Editas Medicine, Inc. (EDIT) Stock Forecast Oct. 13, 2026
Analysis updated on Oct. 13, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Editas Medicine, Inc. (EDIT) stock forecast summary
Our AI ranks Editas Medicine, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
Editas Medicine, Inc. is a small-cap company with a market capitalization of $376M. It ranks number 60 by market capitalization among the 60 Biological Products, (No Diagnostic Substances) issuers in our coverage with a current forecast.
A per-ticker accuracy statistic for EDIT is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.3%, buy ≥ +0.5%, sell < -0.6%, strong sell < -1.7% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-14 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, EDIT included.
Follow EDIT freeEDIT price chart and AI forecast
How EDIT ranks among 4004 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Editas Medicine, Inc. (EDIT) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Biological Products, (No Diagnostic Substances) peers listed below that report each metric.
Reported net income does not reconcile with earnings per share and the share count, so net-income-based ratios are withheld.
Valuation & Market
| Metric | EDIT | Rank |
|---|---|---|
| Market Cap | $376M | 60/60 |
| P/B Ratio | 3.57x | 32/50 |
| EPS | $-1.32 | – |
| Book Value/Share | $0.69 | – |
| Revenue/Share | $0.29 | – |
| FCF/Share | $-0.78 | – |
Profitability & Margins
| Metric | EDIT | Rank |
|---|---|---|
| ROIC | -44.9% | 36/50 |
| Operating Margin | -171.7% | 23/37 |
| EBT Margin | -171.7% | 24/38 |
Financial Health
| Metric | EDIT | Rank |
|---|---|---|
| Current Ratio | 3.19x | 41/54 |
| D/E Ratio | 1.25x | 11/50 |
| Financial Leverage | 2.25x | 11/50 |
| Interest Coverage | -17.5x | 20/38 |
| Working Capital | $150M | 49/54 |
Cash Flow
| Metric | EDIT | Rank |
|---|---|---|
| Operating Cash Flow | -$120M | 26/52 |
| Free Cash Flow | -$121M | 23/45 |
| Capital Spending | -$690K | 6/45 |
| FCF/Sales | -272.9% | 24/30 |
| CapEx/Sales | 1.6% | 24/30 |
Operational Efficiency
| Metric | EDIT | Rank |
|---|---|---|
| Asset Turnover | 0.19x | 22/34 |
| Receivables Turnover | 16.2x | 3/22 |
| Fixed Assets Turnover | 17.2x | 7/34 |
| Days Sales Outstanding | 23 days | 20/22 |
Income Statement
| Metric | EDIT | Rank |
|---|---|---|
| Total Revenue | $44M | 27/34 |
| Operating Income | -$75M | 17/50 |
| R&D Expense | $85M | 42/51 |
Dividend & Shareholder Information
| Metric | EDIT | Rank |
|---|---|---|
| Shares Outstanding | 154M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $218M | 91.9% of assets |
| Cash & Short-term Investments | $182M | 76.6% of assets |
| Accounts Receivable | $3M | 1.2% of assets |
| Total Liabilities | $132M | 55.7% of assets |
| Short-term Debt | $64M | 26.8% of assets |
EDIT quarterly financials and insider trading
Editas Medicine, Inc. (EDIT) industry peers
Companies classified under the same SEC industry code as Editas Medicine, Inc. (Biological Products, (No Diagnostic Substances)): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| EDIT Editas Medicine, Inc. | ▲ | $376M |
| AMGN Amgen Inc | ▼ | $223.19B |
| GILD Gilead Sciences, Inc. | ▶ | $183.41B |
| MRNA Moderna, Inc. | ▲ | $86.33B |
| ARGX Argenx Se | ▶ | $49.67B |
| RVMD Revolution Medicines, Inc. | ▲ | $40.39B |
| BIIB Biogen Inc. | ▼ | $33.79B |
| BNTX Biontech Se | ▶ | $22.51B |
| MESO Mesoblast Ltd | ▼ | $18.02B |
| EXEL Exelixis, Inc. | ▲ | $14.75B |
| NBIX Neurocrine Biosciences Inc | ▼ | $13.74B |
| HALO Halozyme Therapeutics, Inc. | ▲ | $12.44B |
| TECH Bio-Techne Corp | ▼ | $11.37B |
| IBRX Immunitybio, Inc. | ▲ | $10.39B |
| PCVX Vaxcyte, Inc. | ▲ | $9.94B |
| RGEN Repligen Corp | ▲ | $9.90B |
| QGEN Qiagen N.V. | ▼ | $9.86B |
| KRYS Krystal Biotech, Inc. | ▲ | $9.51B |
| TWST Twist Bioscience Corp | ▲ | $9.49B |
| KYMR Kymera Therapeutics, Inc. | ▲ | $8.87B |
| IOVA Iovance Biotherapeutics, Inc. | ▲ | $6.57B |
| IMVT Immunovant, Inc. | ▲ | $5.93B |
| KOD Kodiak Sciences Inc. | ▲ | $5.76B |
| CGON Cg Oncology, Inc. | ▲ | $5.53B |
| SRRK Scholar Rock Holding Corp | ▲ | $4.93B |
| CRSP Crispr Therapeutics Ag | ▲ | $4.84B |
| ADPT Adaptive Biotechnologies Corp | ▲ | $4.03B |
| RLAY Relay Therapeutics, Inc. | ▲ | $3.80B |
| TARS Tarsus Pharmaceuticals, Inc. | ▲ | $3.11B |
| DNLI Denali Therapeutics Inc. | ▲ | $2.94B |
| DBVT Dbv Technologies S.A. | ▼ | $2.67B |
| BEAM Beam Therapeutics Inc. | ▲ | $2.52B |
| ADMA Adma Biologics, Inc. | ▲ | $2.31B |
| NVAX Novavax Inc | ▲ | $2.11B |
| VCEL Vericel Corp | ▶ | $2.06B |
| BCRX Biocryst Pharmaceuticals Inc | ▲ | $2.06B |
| RXRX Recursion Pharmaceuticals, Inc. | ▲ | $2.05B |
| VIR Vir Biotechnology, Inc. | ▲ | $1.80B |
| SCNI Scinai Immunotherapeutics Ltd. | ▶ | $1.71B |
| ALVO Alvotech | ▶ | $1.68B |
| MAZE Maze Therapeutics, Inc. | ▲ | $1.48B |
| IMCR Immunocore Holdings Plc | ▲ | $1.43B |
| COAG Hemab Therapeutics Holdings, Inc. | ▲ | $1.39B |
| TSHA Taysha Gene Therapies, Inc. | ▲ | $1.17B |
| REPL Replimune Group, Inc. | ▲ | $1.14B |
| VOR Vor Biopharma Inc. | ▶ | $1.13B |
| JATT Zura Bio Ltd | ▼ | $1000M |
| VALN Valneva Se | ▼ | $965M |
| MGTX Meiragtx Holdings Plc | ▶ | $955M |
| IMTX Immatics N.V. | ▶ | $916M |
| CGEM Cullinan Therapeutics, Inc. | ▲ | $907M |
| GLUE Monte Rosa Therapeutics, Inc. | ▲ | $844M |
| ODTX Odyssey Therapeutics, Inc. | ▲ | $829M |
| DNA Ginkgo Bioworks Holdings, Inc. | ▲ | $792M |
| SANA Sana Biotechnology, Inc. | ▶ | $721M |
| CADL Candel Therapeutics, Inc. | ▲ | $709M |
| FDMT 4d Molecular Therapeutics, Inc. | ▲ | $682M |
| AURA Aura Biosciences, Inc. | ▲ | $650M |
| SLDB Solid Biosciences Inc. | ▲ | $624M |
| PRME Prime Medicine, Inc. | ▲ | $602M |
Where EDIT sits on the market map
Editas Medicine, Inc. (EDIT) stock news
Loading...
Editas Medicine, Inc. (EDIT) stock forecast FAQ
What is the Editas Medicine, Inc. (EDIT) stock forecast?
Our AI ranks Editas Medicine, Inc. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
How accurate are Editas Medicine, Inc. stock predictions?
A per-ticker accuracy statistic for EDIT is published only once its sample size is known. Across our coverage, the out-of-sample test on 4537 stocks from 2025-01-06 to 2026-06-09 produced a positive net return in 73.7% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Editas Medicine, Inc. forecasts updated?
Editas Medicine, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 13, 2026.
Which companies are Editas Medicine, Inc.'s industry peers?
60 issuers in our coverage, EDIT included, share the SEC industry code Biological Products, (No Diagnostic Substances). The largest are: Amgen Inc (AMGN), Gilead Sciences, Inc. (GILD), Moderna, Inc. (MRNA), Argenx Se (ARGX), Revolution Medicines, Inc. (RVMD), Biogen Inc. (BIIB).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.